B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

NCT04077866 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma
Refractory Glioblastoma

Interventions

DRUG: Temozolomide
BIOLOGICAL: B7-H3 CAR-T

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]